Previous Article | Next Article ![]()
Journal of Virology, November 1998, p. 9016-9024, Vol. 72, No. 11
CRC Institute for Cancer Studies, University
of Birmingham Medical School, Birmingham B15 2TA, United Kingdom
Received 11 May 1998/Accepted 11 August 1998
BHRF1, a component of the restricted early antigen complex of the
Epstein-Barr virus lytic cycle, encodes a 17-kDa protein with both
sequence and functional homology to the antiapoptotic Bcl-2 oncogene.
Recent work has suggested that BHRF1 behaves like Bcl-2 in protecting
cells from apoptosis induced by a range of stimuli. In this study, the
effect of BHRF1 and Bcl-2 on the growth and differentiation of the
SCC12F human epithelial cell line was examined. The levels of stable
transfected BHRF1 expression achievable in SCC12F cells was
consistently lower than that obtained with Bcl-2. While both BHRF1 and
Bcl-2 inhibited epithelial differentiation, the effect of Bcl-2 was
more pronounced, resulting in an almost complete blockade of
differentiation in organotypic raft cultures. However, BHRF1-expressing
SCC12F cells proliferated at a much higher rate than SCC12F cells
expressing Bcl-2, and this effect was supported by cell cycle analysis
which demonstrated that BHRF1, but not Bcl-2, promotes rapid transit
through the cell cycle. These data highlight important differences
between BHRF1 and Bcl-2 and suggest that BHRF1 may function to promote
the survival and proliferation of lytically infected cells. The
proliferative properties of BHRF1 described in this study, together
with the demonstration that other oncogenic gamma herpesviruses encode
Bcl-2 homologues, suggests that these proteins may serve to increase
the susceptibility of virus-infected cells to oncogenic transformation,
thereby contributing to the development of virus-associated tumors.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Functional Differences between BHRF1, the
Epstein-Barr Virus-Encoded Bcl-2 Homologue, and Bcl-2 in Human
Epithelial Cells
*
Corresponding author. Mailing address: CRC Institute
for Cancer Studies, University of Birmingham Medical School, Clinical Research Block, Edgbaston, Birmingham B15 2TA, United Kingdom. Phone:
21 414 7144. Fax: 21 414 5376. E-mail:
L.S.Young{at}bham.ac.uk
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»